Pathway Inhibitor Program(s)
Cancers with specific driver mutations
Pre-clinicalActive
Key Facts
Indication
Cancers with specific driver mutations
Phase
Pre-clinical
Status
Active
Company
About Anastasis Biotec
Anastasis Biotec is an early-stage, private biotech focused on a precision oncology strategy that matches specific cancer-driving mutations with proprietary pathway inhibitors. The company is in the pre-clinical development stage, having raised initial funding through equity crowdfunding to advance its R&D and support external research collaborations. Its goal is to provide a tailored treatment for cancers with significant unmet need, with clinical efficacy data anticipated in four to five years.
View full company profile